ETC
ALLO icon

Exchange Traded Concepts’s Allogene Therapeutics ALLO Stock Holding History

Exchange Traded Concepts’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-68,858
Closed -$101K – 1409
2025
Q1 		$101K Buy
68,858
+8,183
+13% +$15.4K ﹤0.01% 1162
2024
Q4 		$129K Hold
60,675
– – ﹤0.01% 1095
2024
Q3 		$170K Buy
60,675
+12,328
+25% +$32.9K ﹤0.01% 1014
2024
Q2 		$113K Sell
48,347
-15,042
-24% -$44.4K ﹤0.01% 933
2024
Q1 		$283K Buy
63,389
+27,349
+76% +$114K 0.01% 828
2023
Q4 		$116K Buy
36,040
+9,139
+34% +$25.9K ﹤0.01% 871
2023
Q3 		$85.3K Buy
26,901
+1,964
+8% +$8.61K ﹤0.01% 951
2023
Q2 		$124K Buy
+24,937
New +$135K ﹤0.01% 899

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Exchange Traded Concepts's ALLO Position: Q2 2025 in Review

Exchange Traded Concepts sold out of Allogene Therapeutics (ALLO) in Q2 2025, closing a stake of 68,858 shares — an estimated $101K sold.

Exchange Traded Concepts first reported a position in ALLO in Q2 2023 and held it in 8 quarters. The position peaked at $283K in Q1 2024. 158 funds tracked by Wall St. Rank hold ALLO as of Q2 2025.

  • Exchange Traded Concepts reported no remaining Allogene Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Exchange Traded Concepts sold 68,858 Allogene Therapeutics shares in Q2 2025, an estimated $101K.
  • Exchange Traded Concepts first reported a position in Allogene Therapeutics in Q2 2023 and held it in 8 quarters.
  • Exchange Traded Concepts's Allogene Therapeutics position peaked at $283K in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2025.

Based on Exchange Traded Concepts's 13F filing for Q2 2025, filed 10 Jul 2025.